Literature DB >> 3586251

Nicotine replacement in smoking cessation. Absorption of nicotine vapor from smoke-free cigarettes.

M A Russell, M J Jarvis, G Sutherland, C Feyerabend.   

Abstract

Nicotine replacement is a promising new approach to aid smoking cessation, and various methods of delivery are being developed. One new device is a smoke-free cigarette (Favor) that has been test-marketed in several US states. Without lighting up, it delivers nicotine vapor and is free of other harmful products of tobacco smoke. To examine its therapeutic potential, we measured plasma nicotine concentrations before, during, and after its use in eight male subjects. Very little nicotine was absorbed when it was puffed like a conventional cigarette. However, with an intensive schedule of puffing at four further smoke-free cigarettes over a 20-minute period, plasma nicotine concentrations were increased by an average of 17.3 ng/mL (107.3 nmol/L) (range, 10.9 to 30.4 ng/mL [67.6 to 188.5 nmol/L]). Heart rate and blood pressure also increased significantly. The rate of nicotine absorption was slow and resembled that obtained from nicotine chewing gum, suggesting that most of the nicotine was deposited in the mouth, throat, and large airways and did not reach the lung alveoli. Despite the slow absorption, the plasma nicotine levels produced could be of therapeutic value as an aid to smoking cessation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3586251

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  7 in total

1.  Estimating the health consequences of replacing cigarettes with nicotine inhalers.

Authors:  W Sumner
Journal:  Tob Control       Date:  2003-06       Impact factor: 7.552

Review 2.  Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems.

Authors:  N G Schneider; E Lunell; R E Olmstead; K O Fagerström
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

3.  Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study.

Authors:  Y B Bannon; J Corish; O I Corrigan; J G Devane; M Kavanagh; S Mulligan
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms.

Authors:  E Lunell; L Molander; S J Leischow; K O Fagerström
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Risk-benefit assessment of nicotine preparations in smoking cessation.

Authors:  J R Hughes
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

7.  Effect of smoke-free cigarettes on 24 h cigarette withdrawal: a double-blind placebo-controlled study.

Authors:  P Hajek; M J Jarvis; M Belcher; G Sutherland; C Feyerabend
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.